论文部分内容阅读
90年代之后,上海制药工业在全国的领先地位逐渐滑落,到1995年,在全国30个省市自治区药品纯销售额排序中,上海已落到第13位。上海医药工业的销售利润也很低,据报道平均只有1.85％左右,低于全国国有企业平均2.45％～2.88％的水平,与国外制药行业15％左右的销售利润水平相距甚远。再者,上海医药工业缺乏拳头产品,缺乏销售排名前10位的产品。销售量超过1亿元的产品目前只有施尔康系列和泛捷复系列等少数品种。面对这样一种尴尬的局面,昔日的龙头老大如何才能东山再起,在激烈的市场竞争中重新占据自
After the 1990s, the leading position of the Shanghai pharmaceutical industry in the country gradually declined. By 1995, Shanghai ranked 13th in the ranking of pure drug sales in 30 provinces, municipalities, and autonomous regions. Shanghai Pharmaceutical Industry’s sales profit is also very low, it is reported that the average is only about 1.85%, lower than the average state-owned enterprises 2.45% to 2.88% level, and the foreign pharmaceutical industry about 15% of the sales profit margins are far apart. Moreover, the Shanghai pharmaceutical industry lacks competitive products and lacks the top 10 products for sale. Products with a sales volume of more than 100 million yuan currently have only a few varieties such as the Schalcon series and the Pan-Jane series. In the face of such an embarrassing situation, how could the former leader regain its position in the fierce market competition?